# DiaMedica Therapeutics Inc.: financial statements, quarterly

DMAC · Nasdaq · CIK 1401040 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/dmac.md) · [Financials](/companies/dmac/financials.md) · [Filings](/companies/dmac/filings.md) · [Insiders](/companies/dmac/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/dmac/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [3.3](/filings/0001437749-24-034925.md) | [3.7 d](/filings/0001437749-25-008018.md) | [3.7](/filings/0001437749-25-016488.md) | [3.9](/filings/0001437749-25-026207.md) | [5.0](/filings/0001437749-25-034469.md) | [6.5 d](/filings/0001437749-26-010342.md) | [5.7](/filings/0001437749-26-015220.md) | [5.8](/filings/0001437749-26-026792.md) | [6.4](/filings/0001437749-25-034469.md) | [6.7 d](/filings/0001437749-26-010342.md) | [8.0](/filings/0001437749-26-015220.md) | [8.2](/filings/0001437749-26-026792.md) |
| Operating income | $m | [(5.2)](/filings/0001437749-24-034925.md) | [(5.8) d](/filings/0001437749-25-008018.md) | [(5.7)](/filings/0001437749-25-016488.md) | [(5.6)](/filings/0001437749-25-026207.md) | [(6.9)](/filings/0001437749-25-034469.md) | [(8.4) d](/filings/0001437749-26-010342.md) | [(8.1)](/filings/0001437749-26-015220.md) | [(8.0)](/filings/0001437749-26-026792.md) | [(9.0)](/filings/0001437749-25-034469.md) | [(9.2) d](/filings/0001437749-26-010342.md) | [(10.5)](/filings/0001437749-26-015220.md) | [(10.5)](/filings/0001437749-26-026792.md) |
| Income tax | $m | [0.0](/filings/0001437749-24-034925.md) | [0.0 d](/filings/0001437749-25-008018.md) | [0.0](/filings/0001437749-25-016488.md) | [0.0](/filings/0001437749-25-026207.md) | [0.0](/filings/0001437749-25-034469.md) | [0.0 d](/filings/0001437749-26-010342.md) | [0.0](/filings/0001437749-26-015220.md) | [0.0](/filings/0001437749-26-026792.md) | [0.0](/filings/0001437749-25-034469.md) | [0.0 d](/filings/0001437749-26-010342.md) | [0.0](/filings/0001437749-26-015220.md) | [0.0](/filings/0001437749-26-026792.md) |
| Net income | $m | [(4.5)](/filings/0001437749-24-034925.md) | [(5.2) d](/filings/0001437749-25-008018.md) | [(5.2)](/filings/0001437749-25-034469.md) | [(5.1)](/filings/0001437749-25-034469.md) | [(6.3)](/filings/0001437749-25-034469.md) | [(7.9) d](/filings/0001437749-26-010342.md) | [(7.7)](/filings/0001437749-26-026792.md) | [(7.7)](/filings/0001437749-26-026792.md) | [(8.6)](/filings/0001437749-25-034469.md) | [(8.7) d](/filings/0001437749-26-010342.md) | [(10.0)](/filings/0001437749-26-026792.md) | [(10.1)](/filings/0001437749-26-026792.md) |
| Diluted EPS | $ per share | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Basic EPS | $ per share | [(0.12)](/filings/0001437749-24-034925.md) | not reported | [(0.14)](/filings/0001437749-25-016488.md) | [(0.13)](/filings/0001437749-25-026207.md) | [(0.15)](/filings/0001437749-25-034469.md) | not reported | [(0.18)](/filings/0001437749-26-015220.md) | [(0.18)](/filings/0001437749-26-026792.md) | [(0.17)](/filings/0001437749-25-034469.md) | not reported | [(0.19)](/filings/0001437749-26-015220.md) | [(0.19)](/filings/0001437749-26-026792.md) |

- Revenue: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: not reported
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [2.2](/filings/0001437749-23-031671.md) | [4.5](/filings/0001437749-25-008018.md) | [2.1](/filings/0001437749-24-015381.md) | [14.1](/filings/0001437749-24-025198.md) | [4.1](/filings/0001437749-24-034925.md) | [3.0](/filings/0001437749-26-010342.md) | [2.6](/filings/0001437749-25-016488.md) | [4.1](/filings/0001437749-25-026207.md) | [3.3](/filings/0001437749-25-034469.md) | [15.6](/filings/0001437749-26-026792.md) | [4.9](/filings/0001437749-26-015220.md) | [5.1](/filings/0001437749-26-026792.md) |
| Current assets | $m | [47.9](/filings/0001437749-23-031671.md) | [53.7](/filings/0001437749-25-008018.md) | [47.5](/filings/0001437749-24-015381.md) | [55.0](/filings/0001437749-24-025198.md) | [50.8](/filings/0001437749-24-034925.md) | [44.6](/filings/0001437749-26-010342.md) | [37.4](/filings/0001437749-25-016488.md) | [31.1](/filings/0001437749-25-026207.md) | [56.2](/filings/0001437749-25-034469.md) | [60.6](/filings/0001437749-26-026792.md) | [52.4](/filings/0001437749-26-015220.md) | [44.3](/filings/0001437749-26-026792.md) |
| Total assets | $m | [58.1](/filings/0001437749-23-031671.md) | [54.2](/filings/0001437749-25-008018.md) | [49.3](/filings/0001437749-24-015381.md) | [56.8](/filings/0001437749-24-025198.md) | [52.5](/filings/0001437749-24-034925.md) | [46.3](/filings/0001437749-26-010342.md) | [38.8](/filings/0001437749-25-016488.md) | [31.5](/filings/0001437749-25-026207.md) | [57.0](/filings/0001437749-25-034469.md) | [61.4](/filings/0001437749-26-026792.md) | [53.1](/filings/0001437749-26-015220.md) | [45.0](/filings/0001437749-26-026792.md) |
| Current liabilities | $m | [2.2](/filings/0001437749-23-031671.md) | [2.8](/filings/0001437749-25-008018.md) | [2.6](/filings/0001437749-24-015381.md) | [3.1](/filings/0001437749-24-025198.md) | [4.3](/filings/0001437749-24-034925.md) | [5.4](/filings/0001437749-26-010342.md) | [4.7](/filings/0001437749-25-016488.md) | [4.1](/filings/0001437749-25-026207.md) | [5.3](/filings/0001437749-25-034469.md) | [5.1](/filings/0001437749-26-026792.md) | [5.7](/filings/0001437749-26-015220.md) | [6.6](/filings/0001437749-26-026792.md) |
| Shareholders' equity | $m | [55.6](/filings/0001437749-24-034925.md) | [51.1](/filings/0001437749-26-010342.md) | [46.3](/filings/0001437749-25-034469.md) | [53.4](/filings/0001437749-25-034469.md) | [48.0](/filings/0001437749-25-034469.md) | [40.7](/filings/0001437749-26-026792.md) | [34.0](/filings/0001437749-26-026792.md) | [27.2](/filings/0001437749-26-026792.md) | [51.6](/filings/0001437749-25-034469.md) | [56.1](/filings/0001437749-26-026792.md) | [47.2](/filings/0001437749-26-026792.md) | [38.3](/filings/0001437749-26-026792.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(4,797) d](/filings/0001437749-24-034925.md) | [(3,812) d](/filings/0001437749-25-008018.md) | [(6,653)](/filings/0001437749-25-016488.md) | [(4,519) d](/filings/0001437749-25-026207.md) | [(4,470) d](/filings/0001437749-25-034469.md) | [(6,434) d](/filings/0001437749-26-010342.md) | [(7,149)](/filings/0001437749-26-015220.md) | [(7,598) d](/filings/0001437749-26-026792.md) | [(6,550) d](/filings/0001437749-25-034469.md) | [(7,765) d](/filings/0001437749-26-010342.md) | [(9,082)](/filings/0001437749-26-015220.md) | [(8,114) d](/filings/0001437749-26-026792.md) |
| Capital expenditure | $k | [10.0 d](/filings/0001437749-24-034925.md) | [3.0 d](/filings/0001437749-25-008018.md) | [9.0](/filings/0001437749-25-016488.md) | [0.0 d](/filings/0001437749-25-026207.md) | [9.0 d](/filings/0001437749-25-034469.md) | [7.0 d](/filings/0001437749-26-010342.md) | [12.0](/filings/0001437749-26-015220.md) | [6.0 d](/filings/0001437749-26-026792.md) | [16.0 d](/filings/0001437749-25-034469.md) | [6.0 d](/filings/0001437749-26-010342.md) | [8.0](/filings/0001437749-26-015220.md) | [3.0 d](/filings/0001437749-26-026792.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

Shares outstanding: 53,925,697 at 2026-08-03, from the cover of the [10-Q filed 2026-08-10](/filings/0001437749-26-026792.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:38 ET. No prices; not investment advice.